Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)

摘要

Provided herein are methods and kits for predicting and monitoring a cancer patient's response to treatment with a therapeutic agent by measuring the amount of myeloid derived suppressor cells (MDSC) having the profile CDl11b⁺CD33⁺HLA-DR⁻ and/or CDl11b⁺CD33⁺HLA-DR^low, and optionally by further measuring various suppressive features of the patient's immune system. Also provided herein are methods of treating a cancer patient comprising as an initial step determining whether the cancer patient would be responsive to treatment with the therapeutic agent as described above and wherein the patient is found to be responsive, administering the therapeutic agent.